TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03686592

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of body awareness
Description: Questionnaires+ interviews

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement of body awareness
Description: Questionnaires+ interviews
Study: NCT04573660

Intervention type: DEVICE
Intervention: Coronary and peripheral stents
Description: The participants in the Coronary and peripheral stents arm will receive Coronary and peripheral stents

Intervention type: DEVICE
Intervention: Pacing catheters
Description: The participants in the Pacing catheters arm will receive Pacing catheters

Intervention type: DEVICE
Intervention: Vascular plugs
Description: The participants in the Vascular plugs arm will receive Vascular plugs

Intervention type: DEVICE
Intervention: Measurement and imaging (FFR and OCT)
Description: The participants in the Measurement and imaging (FFR and OCT) arm will receive Measurement and imaging (FFR and OCT)

Intervention type: DEVICE
Intervention: Peripheral dilatation catheters
Description: The participants in the Peripheral dilatation catheters will receive Peripheral dilatation catheters

Intervention type: DEVICE
Intervention: Coronary dilatation catheters
Description: The participants in the Coronary dilatation catheters will receive Coronary dilatation catheters

Intervention type: DEVICE
Intervention: Coronary and peripheral guidewires
Description: The participants in the Coronary and peripheral guidewires will receive Coronary and peripheral guidewires

Intervention type: DEVICE
Intervention: Vessel closure/compression devices
Description: The participants in the Vessel closure/compression devices will receive Vessel closure/compression devices

Intervention type: DEVICE
Intervention: Vascular access introducers
Description: The participants in the Vascular access introducers arm will receive Vascular access introducers
Study: NCT02215902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Affinity plasmapheresis
Description: Insert investigational affinity plasma filter into hemodialysis circuit during routine hemodialysis treatments.
Study: NCT04496232

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICSI
Description: Semen processing by density gradient centrifugation followed by sperm selection by PICSI dishes of the first ejaculate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Second ejaculate
Description: Semen processing by density gradient centrifugation for the second ejaculate
Study: NCT03362944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Music Therapy
Description: The intervention consists of a standardized series of Music Therapy tasks, all based at a constant rhythmic pulse.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Passive Music Therapy
Description: The intervention consists of a series of recorded listening tracks, matched in style to the active intervention, all based at a constant rhythmic pulse.
Study: NCT02968810

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Given PO
Study: NCT03758729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3mg/kg + NS 100mL MIV over 1hr every 2 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation Therapy
Study: NCT05452265

Intervention type: PROCEDURE
Intervention: Endoscopic resection
Description: Complete resection of gastric SETs was recommended if the tumor size was \>2 cm, presence of malignant features, or if the patient was symptomatic, declined periodical surveillance, and preferred to undergo diagnostic and therapeutic resection.
Study: NCT00821535

Intervention type: DRUG
Group type: OTHER
Intervention: maraviroc (Selzentry, Celsentri)
Description: 12 subjects will receive a single dose of 300 mg maraviroc (two 150 mg maraviroc commercial tablets) under fasting conditions.
Study: NCT01079780

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ramucirumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ramucirumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study: NCT03468504

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: Participants view the reflective side of a simple mirror which is placed in their mid-sagittal plane to view a mirror reflection of their non-affected limb for 30 mins per day, 3 days per week, for four weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Mirror Therapy
Description: Placebo Mirror Therapy: Participants view the reflective side of a simple mirror which is placed forward/ahead of them in their mid-sagittal plane, and thus cannot see a reflection of either lower limb as their leg does not pass in front of the mirror for 30 mins per day, 3 days per week, for four weeks.~Treadmill Training: Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treadmill
Description: Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Treadmill
Description: Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks.
Study: NCT04325997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laryngoscope with mouth opener
Description: Double-lumen tube combined with mouth gag for laryngoscope intubation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: video laryngoscope with mouth opener
Description: Double-lumen tube combined with mouth gag for video laryngoscope intubation
Study: NCT01565863

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Goal Attainment Program
Description: The Progressive Goal Attainment Program (PGAP) is a behavioral intervention originally developed in Canada at McGill University in order to increase return to work and community integration for individuals who receive worker's compensation. PGAP is the first disability program that is specifically designed to target the psycho-social risk factors of disability. The premise behind PGAP is that inactivity and attitudinal barriers increase work disability, and these issues are a primary cause of unemployment for individuals with physical and mental disabilities. PGAP is a structured, 10-week intervention that focuses upon helping clients develop a planned activity schedule to assist them in resuming desirable life activities.
Study: NCT00853762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept 25 mg
Description: Subjects who received atacicept 25 milligram (mg) subcutaneously (SC) as loading dose twice weekly for first 4 weeks, followed by atacicept 25 mg SC for 32 weeks, in 28063 study will continue with atacicept 25 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept 75 mg
Description: Subjects who received atacicept 75 mg SC as loading dose twice weekly for first 4 weeks, followed by atacicept 75 mg SC for 32 weeks, in 28063 study will continued with atacicept 75 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept 150 mg
Description: Subjects who received atacicept 150 mg SC as loading dose twice weekly for first 4 weeks, followed by atacicept 150 mg SC for 32 weeks, in 28063 study will continue with atacicept 150 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept 150 mg
Description: Subjects who received placebo SC twice weekly for first 4 weeks, followed by placebo SC for 32 weeks, in 28063 study will continue with atacicept 150 mg (without loading dose) SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
Study: NCT01873014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chinese herbs-I
Description: two agent per day, twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chinese herbs-II
Description: two agent per day, twice a day
Study: NCT04568655

Intervention type: DEVICE
Intervention: noninvasive ventilation
Description: noninvasive ventilation to support the COVID-19 patients with respiratory failure
Study: NCT03181308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carotuximab (TRC105)
Description: Anti Endoglin Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPDIVO
Description: Programmed Death Receptor-1
Study: NCT00597259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys plus Entecavir
Description: Pegasys 180 mcg in 0.5 mL solution administered sc once weekly for 24 weeks plus entecavir (0.5mg mg/capsule) 0.5 mg administered po daily for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: ETV 0.5 mg daily monotherapy for 144 weeks
Study: NCT03986099

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring virus load
Description: Near point of care
Study: NCT00687934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA-9090
Description: This is a dose-escalation study. The first cohort will consist of three patients who will receive STA 9090 (ganetespib)during a 1-hour infusion once per week for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive higher amounts of STA-9090 (gantespib) provided that the previous dose was well tolerated during cycle 1 (week 1 - 4). Dose escalation will continue until the maximum tolerated dose (MTD) is determined.
Study: NCT00906243

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV9103
Description: CV9103 encodes for 4 prostate specific antigens.
Study: NCT03541993

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01663623

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Description: Belimumab 10 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: Azathioprine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azathioprine
Description: Azathioprine
Study: NCT00560716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYC116
Description: Dose escalation of CYC116
Study: NCT02251275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tolvaptan tablets (15 or 30 mg) self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later
Study: NCT01548963

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive glycemia control
Description: Blood glucose levels will be maintained by continuous insulin infusion (Actrapid, Novo Nordisk A/S, Bagsvaerd, Danemark - 50 IU/50 ml FR) within normoglycemia limits (4.4 - 6.1 mmol/l)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intensive glycemia control
Description: Blood glucose levels will be maintained by continuous insulin infusion (Actrapid, Novo Nordisk A/S, Bagsvaerd, Danemark - 50 IU/50 ml FR) within normoglycemia limits (4.4 - 6.1 mmol/l)
Study: NCT03836586

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Intervention
Description: This intervention comprises three components: 1) general education about pain (e.g., pain pathways) and a rationale for the intervention (e.g., gate control theory); 2) impact of positive and negative pain-related thoughts on neural process of pain; and 3) a guided imaginal pain exposure exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Education
Description: General information about the neurobiology of pain and knee osteoarthritis will be given to participants assigned to this intervention.
Study: NCT02817139

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDCS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TDCS

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TDCS
Study: NCT04147156

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epley's Maneuver
Description: Treatment with Epley's Maneuver in the ROTUNDUM-chair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Semont Maneuver
Description: Treatment with the Semont Maneuver in the ROTUNDUM-chair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 360 degree vertical rotation
Description: Treatment with 360 degree vertical rotation in the ROTUNDUM-chair
Study: NCT01868568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Administered subcutaneously (s.c., under the skin).
Study: NCT06609993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secondary treatment of postoperative nausea and vomiting (PONV)
Description: Ondansetron (Ondansetron Accord 2mg/ml, 2 ml solution, Accord Healthcare Limited, Great Britain) in a dose of 4 mg will be administered intravenously when incidence of persistent PONV is observed despite the dexamethasone in a dose of 4 mg will be administration intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secondary treatment of postoperative nausea and vomiting (PONV)
Description: Ondansetron (Ondansetron Accord 2mg/ml, 2 ml solution, Accord Healthcare Limited, Great Britain) in a dose of 4 mg will be administered intravenously when incidence of persistent PONV is observed despite the dexamethasone in a dose of 4 mg will be administration intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraopertative fluid challenge (IFC)
Description: 3 mililitre of synthetic colloid will be transfused intravenously per each sudden blood loss of 1 mililitre

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraopertative fluid challenge (IFC)
Description: 3 mililitre of synthetic colloid will be transfused intravenously per each sudden blood loss of 1 mililitre

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraopertative fluid challenge (IFC)
Description: 3 mililitre of synthetic colloid will be transfused intravenously per each sudden blood loss of 1 mililitre

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: postoperative rescue opioid analgesia using morphine
Description: postoperative rescue opioid analgesia will be administered intravenously using 2 miligrams of morphine ((Morfini Sulfas WZF, 20mg/ml, solutio pro iniectione, Polfa Warszawa, Poland)every 10 minutes until postoperative pain perception using NPRS scale will decrease below 4 (NPRS; 0 meant no pain and 10 meant the worst pain imaginable)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: postoperative rescue opioid analgesia using morphine
Description: postoperative rescue opioid analgesia will be administered intravenously using 2 miligrams of morphine ((Morfini Sulfas WZF, 20mg/ml, solutio pro iniectione, Polfa Warszawa, Poland)every 10 minutes until postoperative pain perception using NPRS scale will decrease below 4 (NPRS; 0 meant no pain and 10 meant the worst pain imaginable)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: postoperative rescue opioid analgesia using morphine
Description: postoperative rescue opioid analgesia will be administered intravenously using 2 miligrams of morphine ((Morfini Sulfas WZF, 20mg/ml, solutio pro iniectione, Polfa Warszawa, Poland)every 10 minutes until postoperative pain perception using NPRS scale will decrease below 4 (NPRS; 0 meant no pain and 10 meant the worst pain imaginable)
Study: NCT01868568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Administered subcutaneously (s.c., under the skin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Administered subcutaneously (s.c., under the skin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Administered subcutaneously (s.c., under the skin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart 30
Description: A single dose administered subcutaneously (s.c., under the skin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart 40
Description: A single dose administered subcutaneously (s.c., under the skin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart 45
Description: A single dose administered subcutaneously (s.c., under the skin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart 55
Description: A single dose administered subcutaneously (s.c., under the skin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: A single dose administered subcutaneously (s.c., under the skin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: A single dose administered subcutaneously (s.c., under the skin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: A single dose administered subcutaneously (s.c., under the skin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: A single dose administered subcutaneously (s.c., under the skin).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: A single dose administered subcutaneously (s.c., under the skin).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: A single dose administered subcutaneously (s.c., under the skin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: A single dose administered subcutaneously (s.c., under the skin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: A single dose administered subcutaneously (s.c., under the skin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: A single dose administered subcutaneously (s.c., under the skin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: A single dose administered subcutaneously (s.c., under the skin).
Study: NCT00578903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: Cytoxan will be given at 50 mg/kg per dose for 4 successive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath
Description: Campath will be given at a dose of 3 mg for patients whose weight is between 5 and 15 kg; at a dose of 5 mg for patients whose weight is between 16 and 30 kg; and at a dose of 10 mg for patients whose weight is greater than 30 kg. The last dose of Campath should be 24 hours or more before stem cell infusion.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: TBI will be given at a dose of 200 cGy for 6/6 HLA match and at a dose of 400 cGy in two fractions of 200 cGy each for 5/6 HLA matched donor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK-506
Description: FK-506 will be given at a dose of 0.03 mg/kg/day via continuous infusion over 24 hours from 4pm on day -2 until engraftment or when patient is able to take by mouth (PO), then 0.03 mg/kg PO every 12 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be administered on day +1, day +3, day +6 and day +11 at a dose of 5 mg/m2. The day +11 dose may be omitted at the discretion of the bone marrow transplant (BMT) in-patient attending physician.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell infusion
Description: Where possible patients will receive bone marrow. Marrow will be collected as per National Marrow Donor Program (NMDP) guidelines to provide a volume of 15-20 ml/kg of marrow and/or 2-4 X 10\^8 nucleated cells/kg. In case marrow cannot be collected, peripheral blood stem cell (PBSC) will be substituted. A minimum of 5-6 X 10\^6 CD 34+ cells/kg should be collected, with a target of 10 X 10\^6/kg.
Study: NCT01788761

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Supplemented Group

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Control Group
Study: NCT03703895

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical AFX5931
Description: Active Comparator, Topical AFX5931, a medication combining a small, potent anti-inflammatory molecule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Placebo
Description: Placebo Comparator, Topical Placebo.
Study: NCT04104971

Intervention type: DIAGNOSTIC_TEST
Intervention: blood tests , abdominal US and doppler

Intervention type: DIAGNOSTIC_TEST
Intervention: blood tests , abdominal US and doppler